Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Investigating the immune system

07.01.2013
Immune cells undergo complex processes during their development. If errors occur, the consequences for those who are affected can be fatal. Scientists from the University of Würzburg have now uncovered new details of what happens. These could be a target for new therapies.
As recently as a few decades ago, the following response was feared: following an organ transplant, the patient’s immune system recognizes the transplanted organ as “foreign” and therefore attacks and rejects it. It was not until the discovery, nearly 30 years ago, that the mycotoxin cyclosporin A can prevent the rejection of a transplanted organ that this response lost its capacity to terrify.

“In T cells, which are important cells in the immune system, cyclosporin A inhibits the activation of a group of transcription factors called NFAT factors,” explains Professor Edgar Serfling, a researcher at the University of Würzburg’s Institute of Pathology. At the time, this finding was tantamount to a “revolution in transplantation medicine”. “Thousands of patients owe their lives to cyclosporin A and the inhibition of NFAT factors,” says Serfling.

Now Serfling, his Research Associate Amiya K. Patra, and other scientists at the University of Würzburg have uncovered new details of the interaction between transcription factors and immune cells. Their work has just been published online in the journal Nature Immunology.

The development of T cells

To enable T cells to recognize transplanted organs or pathogenic viruses and bacteria as foreign material, they first have to be “educated”. This education takes place in the thymus – hence the name T cells. There, the immigrant progenitor cells of the cells later known as thymocytes are subjected to various selection processes in which NFAT factors also play an important role. “If errors occur in these processes, this often leads to autoimmune diseases, such as multiple sclerosis, psoriasis, and rheumatism,” explains Serfling. In multiple sclerosis, for example, autoreactive T cells in the brain attack the myelin sheaths of nerve cells, causing the fatal symptoms of this disease.

In the thymus, thymocyte progenitors develop special receptors on their surface where the body’s own transmitter interleukin 7 (IL-7) can dock. After it has docked, IL-7 transmits signals that activate or deactivate numerous genes in the cells. The progenitor cells subsequently divide and evolve into mature thymocytes.
New insights into the development process

As Amiya Patra has now revealed, NFAT factors also play a significant part in these processes: “If a specific NFAT factor is deactivated in mice, the thymocytes remain in their earliest stage of development and no thymus is created,” explains Serfling. However, if the early steps of thymocyte development that are controlled by IL-7 proceed without disruption, the cell soon forms other receptors that are important to its development and the IL-7 receptor disappears.

Though it is not just the absence of the NFAT factor that disrupts cell development; an excess also messes up the process: the development of thymocytes stops, but at a later stage in this case, and again with fatal consequences: “Specific progenitor receptors are created in an uncontrolled manner, with the result that the person affected develops leukemia, and NFAT factors play a critical role in this too,” explains Serfling.

Approach for new therapies

Through their work the Würzburg team has demonstrated that NFAT factors are critically involved not only in the recognition of the body’s own tissue and in immune responses, but also in the “education” of T cells in the thymus. They therefore represent a target structure that will play a key role in therapies for autoimmune diseases and leukemia in the future.

“An alternative NFAT-activation pathway mediated by IL-7 is critical for early thymocyte development”. Amiya K Patra, Andris Avots, René P Zahedi, Thomas Schüler, Albert Sickmann, Ursula Bommhardt & Edgar Serfling; Nature Immunology, doi:10.1038/ni.2507

Contact

Prof. Dr. Edgar Serfling, T: +49 (0)931 31-81207,
e-mail: serfling.e@mail.uni-wuerzburg.de

Robert Emmerich | idw
Further information:
http://www.uni-wuerzburg.de

More articles from Life Sciences:

nachricht Researchers uncover protein-based “cancer signature”
05.12.2016 | Universität Basel

nachricht The Nagoya Protocol Creates Disadvantages for Many Countries when Applied to Microorganisms
05.12.2016 | Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

IHP presents the fastest silicon-based transistor in the world

05.12.2016 | Power and Electrical Engineering

InLight study: insights into chemical processes using light

05.12.2016 | Materials Sciences

High-precision magnetic field sensing

05.12.2016 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>